: iStockAnalyst.com Symbols Feed

WPI: Financial Gauge Analysis For The September 2009 Quarter

Wed, 25 Nov 2009 03:45:55 GMT

In a previous article, we examined Watson Pharmaceuticals' (NYSE: WPI) Income Statement for the third quarter of 2009 and compared the entries on each line to our "look-ahead" estimates.[More...]

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Financially Healthy Stocks With Attractive Valuations

Thu, 20 Aug 2009 18:56:39 GMT

Value Expectations teaches professional investors how to make more informed investment decision evaluating stocks on the basis of corporate performance, valuation, management quality, earnings quality, and other proprietary variables. These variables inevitably help identify companies that are potential long-term investments while avoiding potential torpedoes. However, during the financial crisis, leverage and a week balance sheet played a significant part when investors evaluated a holding. To help our institutional clients navigate the environment The Applied Finance Group (AFG) developed the risk analysis template specifically to model the healthiness of a company’s balance sheet. In addition to the risk analysis template we also developed a template that calculated an Altman Z-Score developed to identify companies that are most likely to go bankrupt. As professional[More...]

Health Care Reform: Five Ways To Profit With Biotech Stocks & Bond Funds

Tue, 30 Jun 2009 22:07:35 GMT

Health Care Reform: Five Ways to Profit With Biotech Stocks & Bond Funds by Marc Lichtenfeld, Advisory Panelist There are a number of health care reform plans on the drawing boards right now, and they all seem to come with mind-numbing sticker shock. The administration’s new plan and Senator Kennedy’s plan are both estimated to cost $1 trillion over 10 years. I’ll believe that when I see it. When was the last time the government completed any project on budget? And I’m not the only one with doubts. Health Systems Innovations, a health care consultant that has worked with private health insurers, estimates that Senator Kennedy’s bill would cost $4 trillion over 10 years. Ouch…[More...]

Four More Ways To Profit From U.S. Healthcare Reform

Thu, 18 Jun 2009 16:01:00 GMT

Both President Obama’s and Senator Kennedy’s healthcare plans are estimated to cost $1 trillion over 10 years.[More...]

Stock Market Report - 06/17/09

Wed, 17 Jun 2009 21:15:51 GMT

Stocks closed mixed today with the Dow Jones Industrial Average and the S&P 500 closing moderately to the downside, while the NASDAQ managed to eek out a gain. The Dow was off 7.49 points to close at 8497.18, NASDAQ was up[More...]

FDA Calendar Updates: Trinity Biotech (Nasdaq: TRIB) Awaiting Two Responses

Wed, 10 Jun 2009 16:20:54 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete res (...)[More...]

Trends Shaping The Health Care Industry: Part 2

Sat, 06 Jun 2009 18:09:00 GMT

If you have not read part one of this three part article, please find the link here. As I have already highlighted, the health care industry is subject to many swings that are caused by macroeconomic variables, regulation, trends, and beliefs. These changes can be hard to pick up on, especially if you are new to the health care industry or if you are not as familiar with it as with more experienced investors. In the first part of this article, I explained how the Obama Administration and the FDA are shaping the environment for health care companies. It is very important to understand the relationship between companies and their stakeholders and the major forces in the[More...]

Stock Picks : Watson (NYSE: WPI)

Wed, 20 May 2009 15:06:00 GMT

This week’s hot stock from a hot sector is Watson Pharmaceuticals Inc. (WPI). Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products primarily in the United States. Watson recently reported and earnings and provided Wall Street strong guidance for the rest of the year, lifting earning per share guidance to between $2.40 and $2.52 per share up from $2.18 to $2.28. This trend should continue as the pharmaceutical company has two new drugs hitting the market as you read this. RAPAFLO, a selective alpha blocker for benign prostatic hyperplasia. GELNIQUE, a urology drug expected to launch in mid-May. Both should contribute to a healthy balance sheet that sees $571 million in cash and marketable[More...]

Earnings Season Is Over - Who Were The Growth Leaders?

Tue, 19 May 2009 03:27:49 GMT

Earnings season is pretty much over now. Many companies managed to beat drastically reduced expectations. As a result, many bears focused on poor earnings quality and the fact that the bar had been lowered so far, it was no great accomplishment to exceed expectations. There were a number of stocks, though, that beat fair and square. We compiled a list of stocks that had increased earnings per share sequentially and year-over-year and increased revenues sequentially and year-over-year. We had 218 stocks that made the list. We then cross referenced this list with the S&P 500 and came up with the following list of 27 stocks: SymbolNameAETAETNA[More...]

Watson Pharmaceuticals Q3 net income down

Fri, 06 Nov 2009 07:47:00 GMT

Watson Pharmaceuticals, a US-based specialty pharmaceutical company, has reported a net income of $63 million, or $0.55 per diluted share, for the third quarter ended September 30, 2009, compared to $71.1 million, or $0.62 per diluted share, for the third quarter ended September 30, 2008.
Net income for the nine months ended September 30, 2009 was $165.1 million, or $1.45 per diluted share, compared to $182 million, or $1.60 per diluted share, for the nine months ended September 30, 2008.
Net revenues were $2.01 billion for the nine months ended September 30, 2009, compared to $1.9 billion, for the prior-year period.

: iStockAnalyst.com Symbols Feed

WPI: Financial Gauge Analysis For The September 2009 Quarter

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Financially Healthy Stocks With Attractive Valuations

Health Care Reform: Five Ways To Profit With Biotech Stocks & Bond Funds

Four More Ways To Profit From U.S. Healthcare Reform

Stock Market Report - 06/17/09

FDA Calendar Updates: Trinity Biotech (Nasdaq: TRIB) Awaiting Two Responses

Trends Shaping The Health Care Industry: Part 2

Stock Picks : Watson (NYSE: WPI)

Earnings Season Is Over - Who Were The Growth Leaders?

Watson Pharmaceuticals Q3 net income down

Omniture Deal a Milestone for Utah's Tech Sector: The $1.8 Billion Price Tag Would Make It the Largest Such Deal in the State's History.

Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2009

FedEx, Beazer Homes, Netflix are big movers

Watson Pharmaceuticals Earnings Stronger Than Expected

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on EXG, WPI, AVY, TTM, RBY and PHK

Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents

Watson Prices $850 Million of Senior Unsecured Notes

Watson Announces Offering of Senior Unsecured Notes

Watson Announces Limited Recall Of Fentanyl Transdermal System

Watson Pharmaceuticals and Arrow Group Receive FTC Second Request

Stellar Pharmaceuticals Announces Record Second Quarter Revenues and Profitability for the First Half

Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG

Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook

Recordati Signs an Agreement With Nycomed for the Co-Marketing of Silodosin in Italy

Form 4 WATSON PHARMACEUTICALS For: Nov 16 Filed by: Stewart Robert A (10K)

Form 3 WATSON PHARMACEUTICALS For: Nov 16 Filed by: Stewart Robert A (10K)

Form 4 JOYCE R TODD For: Oct 30 (10K)

Form 4 Wilkinson George Fred For: Sep 21 (10K)

Form 3 Wilkinson George Fred For: Sep 21 (10K)

Form 4 Mayr Charles M For: Sep 21 (10K)

Form 3 Mayr Charles M For: Sep 21 (10K)

Form 4 BISARO PAUL For: Sep 04 (10K)

Form 4 Russillo Thomas R For: Aug 13 (10K)

Form 4 MUNRO GORDON For: Aug 12 (10K)